Clinicians should consider switching glaucoma medication within the same class

Article

It is essential that clinicians familiarize themselves with the full spectrum of glaucoma medication available, concludes a study published in the March 2009 issue of Current Opinion in Ophthalmology.

It is essential that clinicians familiarize themselves with the full spectrum of glaucoma medication available, concludes a study published in the March 2009 issue of Current Opinion in Ophthalmology.

Simon K. Law, MD of the Jules Stein Eye Institute at the University of California, US conducted a review of currently available medications to discover if treatments in the same class had similar modes of action and potential adverse events, or if switching to certain medications could offer medical, as well as financial, benefits.

Dr Law found that individual patient response may vary significantly, which could result from factors as diverse as medication compliance, adverse events to medication ingredients or drug-receptor interactions.

Because of these varied factors, Dr Law recommended clinicians be fully versed in currently available treatment, to offer each of their patients the most suitable option.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.